LinkedIn Icon
March 19-21, 2019 | Boston, MA

 

 

Day One
March 20, 2019

Day Two
March 21, 2019

08.30
Chair’s Opening Remarks

08.40
Immune Checkpoint Combinations and the Cancer Immunity Cycle in Lung Cancer: An Insight by Beacon

  • Sam Fieldwick Partnerships & Innovations Manager , Beacon Intelligence - Hanson Wade

Synopsis

  • An overview of immune checkpoint clinical trials and drug landscape
  • Analysis of checkpoint combinations in the context of cancer-immunity cycle in lung cancer
  • Beacon’s approach to researching clinical trials and drug development

09.10
T Cell Engagers, Checkpoints and Cytokines to Broaden Immune Responses to Cancer

Synopsis

  • IO therapy is limited by poor immune recognition, multiple checkpoints and insufficient T cell infiltration
  • Xencor’s pipeline is focused on overcoming these obstacles to broaden the reach of IO therapy
  • CD3 bispecifics overcomes limited immune recognition by directly activating T cells by targeting common hematologic and solid tumor specific targets (CD20, CD123, SSTR2). Clinical trials and next gen approaches will be discussed
  • Bispecific checkpoints clinical trials have been initiated at Xencor (DUET studies) targeting PD1, CTLA4, ICOS and LAG3. Rationale, preclinical antitumor activity and clinical plans/updates will be discussed
  • Rationally designed T cell cytokines (IL-15 and others) with T cell targeting and long acting pharmacodynamic preclinical activity will be discussed that potently enhance intratumoral T cell infiltration

09.40
Panel Discussion: Mind the Gap – Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

Synopsis

  • Hear the perspectives from both biological and protein chemistry sides of the discussion, with the goal of honing in on the key areas that each can support one another in tir shared goal of bringing about the new opportunities for developers to pursue
  • Look at the future targets for ICIs and IO combination therapies and assess their true value

10.30
Morning Refreshments

Preclinical Testing and Tumor Modelling

11.00 Pre-Clinical Modeling of Immune Responses to Cancer: From Bench-Side to Clinical Outcomes

 

  • Translatability of pre-clinical murine models in immunooncology.
  • Pre-clinical models for investigating combination therapies.
  • Fundamental differences in the immune system and tumor microenvironments of mice and humans

Mithun Khattar, Scientist & Immuno-Oncology Lead, Takeda

11.30 Stromal-Imposed Immunosuppresion in the Era of Checkpoint Blockade

  • Mesenchymal stromal cells impinge on anti-tumor immunity
  • We still lack a full understanding of the cellular and molecular mechanisms by which stromal-imposed immunosuppression is exerted
  • We have identified a discrete population of FAP+ stromal cells in immune-excluded breast cancers with potent immunomodulatory potentia

Viviana Cremasco, Investigator, Novartis

12.00 Panel Discussion: Reviewing the Future Challenges in Tumor Modeling for IO Combinations

  • Hear the perspectives from both biological and protein chemistry sides of the discussion
  • Look at the future targets for ICI and IO combination therapies

Mithun Khattar, Scientist & Immuno-Oncology Lead, Takeda
Viviana Cremasco, Investigator, Novartis

Clinical Biomarkers, Immunogenicity and Toxicity

11.00 Understanding Immune-Related Toxicities in the Era of Combination Immunotherapies

  • Patterns of immune-related toxicities
  • Factors that determine toxicities
  • Comprehensive program to manage and prevent immune-toxicities

Osama Rahma, Assistant Professor, Dana Faber

11.30 Immunogenicity of I-O Therapeutics: The Good and The Bad

  • I-O therapeutic depended on manipulating immune checkpoints, one consequence of this is an a decreased tolerance including the therapeutic
  • Is it possible that the MOA of I-O therapeutics contribute to immunogenicity to these therapeutics
  • Are I-O combination therapies increasing immunogenicity and are there strategies to screen for this preclinical
  • Strategies to mitigate immunogenicity to I-O therapeutics

Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb

12.00 Panel Discussion: What Are the Solutions to The These Immunogenicity Challenges

  • Consider a framework by which the effects of specific IO combos can be predicted, based on what was learnt in the talks prior
  • Discuss trends that were seen between the previous presentations to solve their respective challenges
  • Look at combining the capabilities of pharma and academia to srolve these problems

Osama Rahma, Assistant Professor, Dana Faber
Jochem Gokelmeier, Associate Director, Bristol-Myers Squibb

12.45
Lunch

Stages 4 – 7: Trafficking and Infiltration of Immune Cells, Improving the Effectiveness Cell Destruction Mechanisms

13.45
Overcoming the Suppressive Tumor Microenvironment: Lessons from Preclinical and Translational Checkpoint Studies

Synopsis

  • The success of checkpoint blockade therapy is still limited by the suppressive tumor microenvironment and immune-cold tumors
  • By better understanding the mechanisms of emerging therapies, we can use therapeutic intervention strategically in the best indications/combinations

14.15
Development of Novel Combination Immunotherapies for Ovarian Cancer and Mesothelioma

  • Mark Poznansky Director, Vaccine and Immunotherapy Center (VIC), Massachusetts General Hospital (MGH) & Associate Professor, Harvard Medical School

Synopsis

• Description of novel products developed at VIC and their preclinical development
• Description of novel computational approaches to guide and predict
immunotherapeutic targeting and responsiveness
• Description of path to first in human studies for novel combinations

14.45
PD-1-Based Bispecific Antibody Therapies

  • Paul Moore Vice President - Cell Biology & Immunology, Macrogenics

Synopsis

  • Bispecific antibody strategies simultaneously targeting the PD-1 axis and an additional non-redundant immune pathway provides opportunity for synergistic biological responses and potentially enhanced therapeutic/safety window above that achieved by simple mAb combinations
  • Three case study programs ranging from concept to clinic will be presented: PD1xLAG3; PD1xCTLA4 and PD-L1xCD137
  • Topics covered will span selection of antibody binding specificities and optimization of molecular structure to match desired biology; preclinical pharmacology including comparison to corresponding mAb combinations; IND enabling studies and clinical study design

 

15.15
Chair’s Closing Remarks